Diabetes
Refine Search
Pharmaceutical
Japan’s largest drugmaker Takeda Pharmaceuticals this morning launched its new type 2 diabetes drug Vipidia (alogliptin) in the UK, its third European launch following Denmark and Switzerland. 26 February 2014
Biotechnology
USA-based biotech firm Celladon has entered into an option agreement with French independent drugmaker Laboratories Servier for a potential worldwide ex-US research collaboration and license agreement for the discovery and development of novel SERCA2b modulators for the treatment of type 2 diabetes and other metabolic diseases. 24 February 2014
Pharmaceutical
UK drugs watchdog the National Institute for Health and Care Excellence is currently appraising Invokana (canagliflozin), from US health care giant Johnson & Johnson subsidiary Janssen-Cilag, when used in combination with other anti-diabetic drugs, including insulin, for the treatment of type 2 diabetes. 24 February 2014
Pharmaceutical
The number of people with diabetes in China is set to soar 37% from 118 million to 162 million by 2030, according to independent analyst firm Datamonitor Healthcare. 19 February 2014
Biotechnology
Privately-held US biotech company MicroBiome Therapeutics has released positive top-line results from a clinical trial of its lead microbiome modulator NM504 in development for type 2 diabetes and pre-diabetes. 18 February 2014
Pharmaceutical
The Indian government's decision to review patented drugs by multinationals, to allow for the manufacture of low cost generic versions, has brought on the ire of the US Chamber of Commerce. The latter has urged its government to ratchet up pressure on India over intellectual property rights, reports The Pharma Letter’s India correspondent. 17 February 2014
Pharmaceutical
The USA’s biopharmaceutical research companies are currently developing 180 innovative new medicines to help the nearly 400 million people who have diabetes worldwide. 12 February 2014
Pharmaceutical
The US Food and Drug Administration has requested clinical trial data from Anglo-Swedish drug major AstraZeneca, the manufacturer of saxagliptin, to investigate a possible association between use of the type 2 diabetes drug and heart failure. 12 February 2014
Pharmaceutical
Type 2 diabetes is one of the most significant global health concerns of modern times. According to the International Diabetes Federation, more than 55 million people have been diagnosed with diabetes in Europe in 2012, and this number is expected to rise to 64 million by 2030. 11 February 2014
Biosimilars
US pharma giant Merck & Co and South Korea’s Samsung Bioepis have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. 11 February 2014
Pharmaceutical
‘Momentum’ is the word which best describes 2013, according to AstraZeneca’s chief executive Pascal Soriot who commented on the firm’s year-end results at a media briefing in London this morning. 6 February 2014
Biosimilars
French drug major Sanofi says it has filed a patent infringement suit against USA pharma firm Eli Lilly in the US District Court for the District of Delaware, alleging infringement of four patents. 31 January 2014
Pharmaceutical
Israeli drugmaker Oramed Pharmaceuticals (NasdaqCM: ORMP) has announced positive results from the Phase IIa clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes. 30 January 2014
Pharmaceutical
Danish insulin giant Novo Nordisk has announced a 15% growth in profit in the firm’s 2013 financial results released today. 30 January 2014
Pharmaceutical
A unique collaboration between leading London hospitals and Danish insulin giant Novo Nordisk (NOV: N) launched the i3-diabetes program today, which aims to put people with diabetes at the center of their care by integrating specialist services around their needs. 27 January 2014
Pharmaceutical
The Association of Pharmaceutical Research and Development and the American Chamber of Commerce in Ukraine have recently sent an open letter to the Minister of Health of Ukraine, which aimed to draw attention to the problems of providing patients with insulin and their possible solutions. 27 January 2014
Pharmaceutical
Among a batch of positive opinions issued today by the European Medicines Agency’ s Committee for Medicinal Products for Human Use (CHMP), there was good news for UK pharma giant GlaxoSmithKline relating to Eperzan (albiglutide). 24 January 2014
Pharmaceutical
The European Commission has approved Anglo-Swedish drug major AstraZeneca and soon to be ex-partner USA-based Bristol-Myers Squibb’s Xigduo (dapagliflozin and metformin hydrochloride) for the treatment of type 2 diabetes in the European Union. 22 January 2014
Pharmaceutical
Japanese drug major Astellas Pharma has obtained the marketing approval of selective SGLT2 inhibitor Suglat tablets (ipragliflozin L-proline; development code: ASP1941) for the treatment of type 2 diabetes in Japan. Astellas filed an application for approval in March 2013. 20 January 2014
Pharmaceutical
Zealand Pharma and Boehringer Ingelheim will change the development program involving novel glucagon/GLP-1 dual agonists for the treatment of type 2 diabetes and/or obesity with the selection of a new lead compound that will replace ZP2929 under the collaboration between the two companies. 20 January 2014
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Biotechnology
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. 7 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze